NAFLD与肝细胞癌的相关性研究进展*

doi:10.3969/j.issn.1672-5069.2018.05.046

Abstract

Abstract: Non-alcoholic fatty liver disease （NAFLD）,involvement of metabolic syndrome,is being the most common liver disease worldwide. The spectrum of NAFLD ranges from simple steatosis to NASH,finally leading to liver cirrhosis and hepatocellular carcinoma（HCC）. As the obesity is becoming global problem,the incidence of NAFLD,NASH and NAFLD/NASH-associated cirrhosis and NAFLD/NASH-associated HCC is increasing gradually. In recent years,many scholars believe that HCC might arise in the absence of overt cirrhosis in patients with NASH,and the mechanism for the switch remains elusive. The review will focus on the relationship between NAFLD and HCC.

Key words: Nonalcoholic fatty liver disease, Hepatocellular carcinoma, Metabolic syndrome

Bing Hao, Li Yiling.. Correlation between non-alcoholic fatty liver disease and hepatocellular carcinoma:Fact or fiction[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 821-824.

References

[1] Hassan K,Bhalla V,El Regal ME,et al.Nonalcoholic fatty liver disease:A comprehensive review of a growing epidemic. World J Gastroenterol,2014, 20(34): 12082-12101.
[2] Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes. Hepatology,2016,64(1): 73-84.
[3] Fan J.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol,2013,28:11-17.
[4] De Minicis S,Day C,Svegliati-Baroni G.From NAFLD to NASH and HCC:Pathogenetic mechanisms and therapeutic insights. Curr Pharmaceut Des,2013,19(29):5239-5249.
[5] Powell EE,Cooksley WG,Hanson R, et al.The natural history of nonalcoholic steatohepatitis:A follow-up study of forty-two patients for up to 21 years. Hepatology,1990,11(1):74-80.
[6] Rosmorduc O,Fartoux L. HCC and NASH: How strong is the clinical demonstration Clin Res Hepatol Gastroenterol,2012,36(3):202-208.
[7] Sanyal A,Poklepovic A,Moyneur E,et al.Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin,2010,26(9):2183-2191.
[8] White DL,Kanwal F,El Serag HB.Non-alcoholic fatty liver disease and hepatocellular cancer:A systematic review. Clin Gastroenterol Hepatol,2012,10(12):1342-1359.
[9] Said A,Ghufran A.Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma. World J Clin Oncol,2017,8(6):429-436.
[10] Duan X,Zhang L,Fan J,et al.NAFLD leads to liver cancer: Do we have sufficient evidence. Cancer Lett,2014,345(2):230-234.
[11] Ascha MS,Hanouneh IA,Lopez R,et al.The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology,2010,51(6):1972-1978.
[12] Bugianesi E,Leone N,Vanni E,et al.Expanding the natural history of nonalcoholic steatohepatitis:From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology,2002,123(1):134-140.
[13] Marrero JA,Fontana RJ,Su GL,et al.NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology,2002,36(6):1349-1354.
[14] Michelotti GA,Machado MV,Diehl AM.NAFLD,NASH and liver cancer. Nature Reviews. Gastroenterol Hepatol,2013,10(11):656-665.
[15] Alexander J,Torbenson M,Wu TT,et al.Nonalcoholic fatty liver disease contributes to hepatocellular carcinoma in non-cirrhotic liver:A clinical and pathological study. Gastroenterol Hepatol,2013,28(5):848-854.
[16] Polesel J,Zucchetto A,Montella M,et al.The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol,2008,20(2):353-357.
[17] Calle EE,Rodriguez C,Walker-Thurmond K,et al.Overweight, obesity,and mortality from cancer in a prospectively studied cohort of US. N Engl J Med,2003,348(17):1625-1638.
[18] Yu J,Shen J,Sun TT,et al.Obesity,insulin resistance,NASH and hepatocellular carcinoma. Sem Cancer Biol,2013,23(6):483-491.
[19] Wang P,Kang DH,Cao W,et al.Diabetes mellitus and risk of hepatocellular carcinoma:A systematic review and meta-analysis. Diabetes Metab Res Rev,2012,28(2):109-122.
[20] Hassan MM,Hwang LY,Hatten CJ,et al.Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology,2002,36(5): 1206-1213.
[21] Chen CL,Yang HI,Yang WS,et al.Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection:A follow-up study in Taiwan. Gastroenterology,2008,135(1): 111-121.
[22] Park EJ,Lee JH,Yu G,et al.Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell,2010,140(2):197-208.
[23] Kamada Y,Matsumoto H,Tamura S,et al.Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model. Hepatology,2007,47(4):556-564.
[24] Margini C,Dufour JF.The story of HCC in NAFLD:From epidemiology,across pathogenesis,to prevention and treatment. Liver Int,2016,36(3):317-324.
[25] Starley BQ,Calcagno CJ,Harrison SA.Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology,2010, 1(5):1820-1832.
[26] Sorrentino P,D Angelo S,Ferbo U,et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. Hepatology,2009,50(2):351-357.
[27] Shen JH,Li YL,Li D, et al.The rs738409(I148M) variant of the PNPLA3 gene and cirrhosis:A meta-analysis. J Lipid Res,2015,56(1):167-175.
[28] Trepo E,Romeo S,Zucman-Rossi J,et al.PNPLA3 gene in liver diseases. J Hepatol,2016,65(2):399-412.
[29] Jang WY,Bae KB,Kim SH,et al.Overexpression of Jazf1 reduces body weight gain and regulates lipid metabolism in high fat diet. Bioch Biophy Res Commun,2014,444(3):296-301.
[30] Alharbi KK,Ali KI,Syed R,et al.Association of JAZF1 and TSPAN8/LGR5 variants in relation to type 2 diabetes mellitus in a Saudi population. Diabetol Metab Syndr,2015,7(1):92.
[31] Ueyama M,Nishida N,Korenaga M,et al.The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. Gastroenterology,2016,51(4):370-379.
[32] Kozlitina J,Smagris E,Stender S,et al.Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet,2014,46(4):352-356.
[33] Falleti E,Cussigh A,Cmet S,et al.PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis. Dig Liver Dis,2016,48(1):69-75.
[34] Paradis V,Albuquerque M,Mebarki M,et al.Cullin7:a new gene involved in liver carcinogenesis related to metabolic syndrome. Gut,2013,62(6):911-919.
[35] Weinmann A,Alt Y,Koch S,et al.Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer,2015,15(1):210.
[36] Piguet AC,Saran U,Simillion C,et al.Regular exercise decreases liver tumors development in hepatocyte-specifc PTEN-defcient mice independently of steatosis. Hepatology,2015,62(6):1296-1303.

Correlation between non-alcoholic fatty liver disease and hepatocellular carcinoma:Fact or fiction

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[2]	Ren Yufei, Chen Xiaoqing, Kong Weizong, et al.. Effect of salvianolic acid B on autophagy in nonalcoholic fatty liver disease cell model in vitro [J]. Journal of Practical Hepatology, 2019, 22(6): 804-807.
[3]	Li Yingyi, Guo Cuifen, Zhang Ruinan, et al.. Correlation of polymorphism of ALDH2 rs671 to morbidity in individuals prone to nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(6): 848-851.
[4]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[5]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[6]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[7]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[8]	Zhang Lanhua, Shao Qin, Xia Zhenjuan. Changes of serum 25-(OH) D3 and IL-17 levels are associated with progress of nonalcoholic fatty liver disease in obese children [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 522-525.
[9]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[10]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[11]	Huo Huiqin, Gong Xiaohong, Li Zhenghong. Assessment of right atrial and ventricular functions in patients with nonalcoholic fatty liver disease-induced liver cirrhosis by real-time three-dimensional echocardiography and speckle tracking imaging [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 244-247.
[12]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[13]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[14]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[15]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.